Pathway analysis revealed significant downregulation of noncanonical NF-κB signaling in IBD patients responsive to anti-TNFα therapy compared to untreated IBD patients and IBD patients treated with other (non-anti-TNF) medications (Figures 2C–F). This evidence concerns the gene NFKB1 and inflammatory bowel disease.